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Oncolytic Herpes Simplex Virus 1 Encoding 15-Prostaglandin Dehydrogenase
Mitigates Immune Suppression and Reduces Ectopic Primary
and Metastatic Breast Cancer in Mice䌤
Jason D. Walker,1 Inder Sehgal,2 and Konstantin G. Kousoulas1*
Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences, School of Veterinary Medicine,1
and Department of Comparative Biomedical Sciences, School of Veterinary Medicine,2 Louisiana State University,
Baton Rouge, Louisiana 70803

Oncolytic herpes simplex virus 1 (HSV-1) viruses armed with immunomodulatory transgenes have shown
potential for enhanced antitumor therapy by overcoming tumor-based immune suppression and promoting
antitumor effector cell development. Previously, we reported that the new oncolytic HSV-1 virus, OncSyn (OS),
engineered to fuse tumor cells, prevented tumor growth and metastasis to distal organs in the 4T1/BALB/c
immunocompetent breast cancer mouse model, suggesting the elicitation of antitumor immune responses
(Israyelyan et al., Hum. Gen. Ther. 18:5, 2007, and Israyelyan et al., Virol. J. 5:68, 2008). The OSV virus was
constructed by deleting the OS viral host shutoff gene (vhs; UL41) to further attenuate the virus and permit
dendritic cell activation and antigen presentation. Subsequently, the OSVP virus was constructed by inserting
into the OSV viral genome a murine 15-prostaglandin dehydrogenase (15-PGDH) expression cassette, designed
to constitutively express 15-PGDH upon infection. 15-PGDH is a tumor suppressor protein and the primary
enzyme responsible for the degradation of prostaglandin E2 (PGE2), which is known to promote tumor
development. OSVP, OSV, and OS treatment of 4T1 tumors in BALB/c mice effectively reduced primary tumor
growth and inhibited metastatic development of secondary tumors. OSVP was able to significantly inhibit the
development and accumulation of 4T1 metastatic tumor cells in the lungs of treated mice. Ex vivo analysis of
immune cells following treatment showed increased inflammatory cytokine production and the presence of
mature dendritic cells for the OSVP, OSV, and OS viruses. A statistically significant decrease in splenic
myeloid-derived suppressor cells (MDSC) was observed only for OSVP-treated mice. These results show that
intratumoral oncolytic herpes is highly immunogenic and suggest that 15-PGDH expression by OSVP enhanced the antitumor immune response initiated by viral infection of primary tumor cells, leading to reduced
development of pulmonary metastases. The availability of the OSVP genome as a bacterial artificial chromosome allows for the rapid insertion of additional immunomodulatory genes that could further assist in the
induction of potent antitumor immune responses against primary and metastatic tumors.
herpesvirus OncSyn (OS) was effective at treating primary
solid breast tumors in mice (25, 26). Moreover, treatment of
primary 4T1 tumors in syngeneic BALB/c mice with OS led to
a substantial reduction in the formation of metastatic foci
within multiple organs and in some cases eliminated lung metastasis, suggesting the development of effective antitumor immunity (43).
The HSV-1 vhs gene product encoded by the UL41 open
reading frame (ORF) has multiple functions that are known to
suppress antiviral immune responses. (i) vhs is an RNase that
degrades viral and cellular mRNAs, limiting host and viral
antigen production (3, 32, 33, 45, 48, 51, 56, 59, 61, 65, 75). (ii)
UL41 (vhs) with ICP47 is known to inhibit major histocompatibility complex I (MHC-I) antigen presentation (59), while vhs
alone has also been implicated in the reduction of MHC-II
expression (69). (iii) vhs has been reported to suppress production of cytokines and chemokines and inactivate dendritic
cells (7, 59). In agreement with these reports, deletion of the
vhs gene prevented HSV-1-mediated inactivation of antigen
presentation by dendritic cells (DC) (54) and improved the
immunogenicity of a candidate replication-defective HSV-1
vaccine strain (16, 55). Furthermore, deletion of the vhs gene
causes substantial reduction in neurovirulence (48, 60, 64).

Oncolytic human herpes simplex viruses (HSV) have been
genetically engineered to limit neurovirulence and the establishment of latency and reactivation and to replicate exclusively
in cells with deficient apoptotic mechanisms (i.e., cancer cells)
(5, 6, 37). These genetic changes are fundamental to the safety
and efficacy of oncolytic herpesviruses but often result in rapid
clearance of the virus by the host immune response, thus limiting its therapeutic potential. It is precisely the antiviral immune response, however, that is thought to help overcome
tumor-induced immune suppression, allowing for antitumor
immunity to develop. In this regard, HSV-1 infections within
tumors may function as in situ vaccines, providing the necessary inflammatory signals that engage innate and adaptive immune responses to tumor antigens. Thus, oncolytic HSV-1 may
be effective both directly as a cancer killing agent and indirectly
as an immunological enhancer, or in situ cancer vaccine (13,
49). Previously, we reported that the novel fusogenic oncolytic
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It is generally assumed that advanced tumors promote the
formation of an immunosuppressive and tolerogenic microenvironment that subverts the innate immune response, leading
to the inhibition of antitumor adaptive immune responses (14,
46, 76). Tumor-derived immunomodulation may include alteration of tumor antigen expression to render tumor cells less
detectable by the immune system, secretion of factors and
cytokines that inhibit dendritic and T cell functions, and induction of immune cells that can suppress antitumor immune
responses, including myeloid suppressor cells (MDSC) and
regulatory T cells (Treg) (44).
A prominent immunosuppressive factor in many cancers is
prostaglandin E2 (PGE2). PGE2 is a short-lived lipid-based
signaling molecule with potent localized paracrine and autocrine functions that is particularly important for tumor development. PGE2 has been shown to promote tumor angiogenesis
(38, 71), drug resistance (36), invasion and migration (35),
immune suppression (24, 72, 73), and the inhibition of apoptosis (34). PGE2 is generated by tumors and tumor-associated
immune cells from arachidonic acid, with the rate-limiting step
being the enzymatic activity of cyclo-oxygenase 2 (COX-2).
PGE2 is negatively regulated by rapid conversion to 15-keto
metabolites by 15-prostaglandin dehydrogenase (PGDH), an
enzyme with both intra- and extracellular functions. Not surprisingly, 15-PGDH is a tumor suppressor (2, 9, 42, 74), and
loss of 15-PGDH expression in a variety of cancers often accompanies COX-2 upregulation and can be correlated with
disease progression (2, 35, 66, 67, 70). Elevated levels of tumor-associated COX-2, coupled with a loss of PGDH expression, allows many tumors to maintain high levels of PGE2,
which is a poor prognostic indicator and is considered to be an
important step in the evolution of malignant cancers (reviewed
in reference 21). COX-2 activity in tumors may be blocked
using selective or nonselective inhibitors whose use has been
shown to significantly decrease cancer risk for a wide range of
cancer types (reviewed in references 22 and 23, respectively);
however, systemic COX-2 inhibition has side effects that are
poorly tolerated. Transient localized restoration of PGDH expression in tumors using targeted adenoviral vectors has been
shown to inhibit PGE2 accumulation and tumor angiogenesis
and growth (27). Overall, tumor-associated PGE2 is strongly
associated with immune suppression and cancer progression.
Novel anticancer immune therapies designed to limit PGE2
signaling could promote stronger immune responses and inhibit tumor development.
In the present study, we have constructed and characterized
a third-generation recombinant oncolytic viral vector (OSVP)
designed to be more immunogenic than the parental OS virus
due largely to deletion of the viral host shutoff (vhs) gene.
Furthermore, we constructed the OSVP virus to constitutively
express 15-PGDH, the principal enzyme responsible for degradation of PGE2. We show that infection of 4T1 breast tumors implanted in syngeneic and immunocompetent BALB/c
mice with OSVP inhibits metastasis, triggers substantial inflammatory cytokine production, and promotes antitumor immune responsiveness.
MATERIALS AND METHODS
Cells. African green monkey kidney (Vero) cells and mouse mammary tumor
cells (4T1) (1) were obtained from the American Type Culture Collection (Ma-
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nassas, VA). Vero cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (FCS) and antibiotics. 4T1 cells and
primary mouse cells were maintained in RPMI 1640 medium containing 10%
FCS (Invitrogen, Carlsbad CA). The cultures were maintained at 37°C in a
humidified atmosphere of 5% CO2.
Construction of recombinant OSV and OSVP viruses. The previously published OS viral genome recovered as a bacterial artificial chromosome (BAC) in
Escherichia coli (pOS) (26) was used for the construction of the pOSV BAC
plasmid. The coding region of UL41 (nucleotides 91111 to 92638) was deleted to
yield pOSV using double-red mutagenesis in E. coli (68). The OSV virus was
recovered after transfection of Vero cells with pOSV. pOSVP was generated
from pOSV by inserting an ⬃3.1-kbp gene expression cassette containing the
Mus 15-musculus hydroxyprostaglandin dehydrogenase (15-NAD) cDNA
(cDNA clone MGC:14001 IMAGE:4208980) under the control of the human
cytomegalovirus immediate-early HCMV IE promoter. The inserted gene cassette includes nucleotide sequences beginning 12 nucleotides proximal to the
ClaI restriction site and extending to 7 nucleotides before the NsiI restriction site
of the 15-NAD gene. This fragment was inserted into the locus previously
occupied by UL41, in the same genomic orientation as UL41 (right to left). The
OSVP virus was recovered after transfection of Vero cells with pOSVP. These
modifications were confirmed by restriction enzyme and DNA sequence analyses
of the affected genomic regions.
Phenotypic characterization and replication kinetics of the OSV and OSVP
viruses. Cells (both Vero and 4T1) were seeded into 6-well plates and infected
the following day (when they had reached approximately 95% confluence) with
either the HSV-1(F) strain, OS, OSV, or OSVP at a multiplicity of infection
(MOI) ranging from 0.001 to 1 PFU/cell. Cells were cultured in a maintenance
medium (containing 2% FCS) and were left for 2 days to allow for cytopathic
effects to develop. Infected cells were visualized by immunohistochemistry at
48 h postinfection (h.p.i.) using horseradish peroxidase-conjugated anti-HSV
antibody (Dako, Carpinteria, CA) and the Novared substrate development kit
(VectorLabs, Burlingame, CA). Images were captured using phase-contrast microscopy, as reported previously (26).
To determine the replication kinetics of the viruses, one-step growth kinetics
and viral titers at 48 h.p.i. were determined as described previously (11, 12).
Briefly, nearly confluent monolayers of either Vero or 4T1 cells were infected
with each virus at an MOI of 5 at 4°C for 1 h. Thereafter, virus was allowed to
penetrate for 2 h at 37°C. Any remaining extracellular virus was inactivated by
low-pH treatment with phosphate-buffered saline (PBS) at pH 3.0. Supernatants
were harvested at given time points following normal culture conditions, and
viral titers were obtained by endpoint titration on Vero cells.
15-PGDH activity. Transfection of Vero cells with the 15-PGDH mammalian
expression vector was achieved using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s suggested protocol. Cell culture supernatant PGE2 levels
were determined by enzyme-linked immunosorbent assay (ELISA) using Prostaglandin E2 Express EIA kits (Cayman Chemical, Ann Arbor, MI).
4T1 BALB/c tumor growth and pulmonary metastasis determinations. Female
BALB/c mice were obtained from Charles River (Wilmington, MA) and housed
in an animal room which was kept at 25°C with a 12-h light-dark cycle. All
experimental procedures involving animals were approved by the institutional
animal care and use committee (IACUC) of the Louisiana State University. At
6 to 7 weeks of age, 1 ⫻ 105 viable 4T1 cells suspended in 0.1 ml of PBS with 20%
growth factor reduced Matrigel (BD Biosciences, Franklin Lakes, NJ) were
implanted subcutaneously in the interscapular area of the animals by the use of
a 27-gauge needle. Tumor sizes were monitored beginning ⬃7 days after tumor
inoculation by direct measuring with a digital microcaliper. Tumor volumes were
calculated using the following formula: volume ⫽ (length ⫻ width ⫻ height)/2,
as reported previously (26). At an average tumor volume of approximately 200
mm3 (12 days post-tumor inoculation), animals were randomized into 4 groups.
The groups of mice received 3 intratumoral injections of the OS, OSV, or OSVP
viral particles or PBS every 4 days. Virus was prepared by brief centrifugation to
clear cellular debris and diluted to the appropriate concentration of PFU using
PBS. Each tumor was injected with approximately 1 ⫻ 107 PFU per injection in
a 0.1-ml volume, while control mice received PBS. Injections were performed
slowly at 2 different sites per tumor. Heat inactivation of virus was achieved by
incubation at 95°C for 20 min.
For pulmonary metastatic burden assays, tumor-bearing mice treated as above
were euthanized with CO2 at days 29 to 30 post-tumor inoculation. Lungs from
each mouse were excised, minced, and digested for 75 min at 4°C while rocking
in buffer containing elastase and collagenase type IV. Following filtration
through a 100-m nylon screen, total lung homogenates for each mouse were
serially diluted and cultured for 1 week in RPMI 1640 with 10% FBS and 60 M
6-thioguanine. 6-Thioguanine-resistant colonies were formalin fixed and stained

Downloaded from https://journals.asm.org/journal/jvi on 14 January 2022 by 2620:105:b001:1060:86f:667c:32f5:4ae9.

7364

HSV-1 ONCOLYTIC VIRUS ENCODING 15-PGDH

7365

FIG. 1. Schematic representation of the genomic structure of oncolytic recombinant viruses OSV and OSVP. (A) Representation of the
prototypic arrangement of the HSV-1 OncSyn (OS) genome with the unique long (UL) and unique short (US) regions flanked by the terminal
repeat (TR) regions. The ⌬ denotes the approximate location of the OS genomic deletion between the UL and US regions (26), and the position
of the gB syncytial mutation is indicated. The expanded area below the depicted genome shows the genomic region from 84531 to 96068
nucleotides encompassing the UL38-UL43 genes. (B) Genomic organization of the OSV recombinant virus showing deletion of the UL41 gene.
(C) Genomic organization of the OSVP recombinant virus showing insertion of the 15-PGDH gene cassette in place of the deleted UL41
sequences. SV40, simian virus 40.

with crystal violet for visualization and counting. Stained colonies with ⬎20 cells
were counted, with each colony representing one clonogenic metastatic cell (50).
Immunophenotyping of mouse splenocytes and lymphocytes. All analyses were
conducted using freshly harvested splenocytes or by draining lymph node cells
from animals with similarly sized tumors (150 ⫾ 25 mm3). Animals were treated
twice (day 1 and day 4) with PBS, OS, OSV, or OSVP, and spleens and draining
lymph nodes were harvested on day 5. The organs were manually dissociated in
RPMI and filtered through a 100-m nylon mesh. Erythrocytes were removed by
5-min exposure to ACK (150 mM NH4Cl, 0.1 mM EDTA, 10 mM KHCO3; pH
7.3) lysing buffer. Cells for flow cytometry were surface labeled with fluorescently
conjugated antibodies to either murine CD83 (catalog number 558205, BD
Biosciences) to identify activated lymphocytes and dendritic cells, or CD11b and
Gr-1 (catalog numbers 552850 and 553126, respectively; BD Biosciences) to
identify MDSC. Species-appropriate isotype control antibody conjugates were
used in each experiment to identify positive populations (catalog numbers
554685, 552849, and 556923, respectively; BD Biosciences). Regulatory T cells
(Treg) were labeled using the mouse Treg flow kit from Biolegend, San
Diego, CA (catalog number 320015), according to the manufacturer’s instructions. All cytometric datum acquisition was performed on a FACScalibur
instrument (BD Biosciences) and analyzed using WinMDI flow cytometry
analysis freeware (written by Joseph Trotter, The Scripps Research Institute,
La Jolla, CA).
For ex vivo effector cytokine production analyses, splenocytes were cultured ex
vivo in a 96-well format in either control or anti-mouse CD3-coated tissue culture
plates (both from BD Biosciences, catalog numbers 354720 and 354730) in
triplicate at a density of 100,000 cells per well. Supernatants were harvested after
24-h incubation and analyzed for murine Th1 and Th2 cytokine production
(Bio-Plex Pro Mouse cytokine TH1/TH2 assay catalog number M60-00003J7;
Bio-Rad, Hercules, CA).
Statistical analyses. Unless otherwise indicated, Student’s t test was used to
determine P values and establish significant differences for sample means (P ⬍
0.05). Tumor growth curve analyses used a distribution-free test established for
tumor growth curve comparisons (31). Pulmonary 4T1 metastatic burden comparisons were conducted using the Mann-Whitney nonparametric statistical hypothesis test (P ⬍ 0.05, one tailed) supplied on GraphPad software (GraphPad
Software, Inc., La Jolla, CA).

RESULTS
Construction and characterization of HSV-1 OSVP. The
recombinant viruses OSV and OSVP were constructed by double-red mutagenesis of the HSV OS genome cloned into a
bacterial artificial chromosome (BAC) (26). The OS viral genome lacks a section of the HSV-1 large inverted repeat region
encompassing a single copy each of the ICP0, ␥34.5, and ICP4
genes. This region was replaced by a gene cassette constitutively expressing the red fluorescence protein (RFP; HcRed)
under the eukaryotic translation elongation factor 1-a promoter control. In addition, the OS genome contains the gBsyn3
syncytial mutation that causes extensive virus-induced cell fusion (Fig. 1A) (25, 26). The double-red recombination method
(68) was utilized to delete the entire UL41 ORF (vhs) of the
OS BAC (bOS) to produce the OSV BAC (bOSV) and OSV
virus, as described in Materials and Methods (Fig. 1B). The
bOSV genome was used for a subsequent round of double-red
recombination in which a gene cassette containing the murine
15-PGDH under the control of a CMV promoter was inserted
into the vhs deletion site. The resulting bOSVP genome was
transfected into Vero cells to recover the OSVP virus (Fig.
1C). The genotypes of OSV and OSVP viral genomes were
confirmed by direct DNA sequencing (see Materials and
Methods).
The replication and average plaque morphology characteristics of the OSV and OSVP viruses were compared to those of
their parental virus OS and the prototypic HSV-1(F) strain
used to derive the OS virus in cell culture experiments (Fig.
2A). The OS virus produced syncytial plaques that were, on the
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FIG. 2. Plaque morphology and growth characteristics of OS OSV
and OSVP. (A) Nearly confluent Vero cell monolayers were infected
with wild-type HSV-1(F), OS, OSV, or OSVP viruses at MOI of 0.001.
Individual viral plaques were visualized 48 h postinfection by immunohistochemistry and photographed at the same magnification with a
phase-contrast microscope. (B) A minimum of 30 plaques for each
virus (prepared as described in the legend to panel A) were measured,
and individual plaque sizes are indicated on the x axis, with the horizontal bar indicating the means for each group. Error bars indicate
standard error of the means. All pairwise comparisons of the means
using two-tailed t tests indicated significance (P ⬍ 0.0185) except for
the comparison between OSV and OSVP (P ⫽ 0.1473). (C) Nearly
confluent 4T1 cell monolayers were infected with the above-mentioned
viruses at an MOI of 5. Triplicate culture supernatants were collected
at 48 hpi, and viral titers were determined (PFU/ml).

average, larger than those of the prototypic HSV-1(F) at
48 h.p.i. Deletion of the UL41 gene did not appreciably affect
plaque morphology of the resultant OSV virus, in as much as
the viral plaques remained syncytial and OSVP produced
plaques of sizes similar to those produced by the OS virus (Fig.
2B). Both OSV and OSVP produced strong syncytial plaque
phenotypes (Fig. 2A) and caused extensive virus-induced cell

fusion, especially in high-MOI infections of Vero cell monolayers (data not shown).
The ability of the OS, OSV, and OSVP viruses to replicate
in 4T1 cells was examined by determining viral titers obtained
at 48 h.p.i. with an MOI of 5 (Fig. 2B). OSVP produced viral
titers that were approximately one log lower than the OSV
virus, while OSV produced intermediate titers approximately
5-fold lower than those of the OS virus. Additional experiments in Vero cells revealed a similar virus production pattern,
with OSVP producing consistently approximately one log less
virus than the OS virus (not shown).
OSVP inhibits PGE2 accumulation. To evaluate the ability
of the OSVP virus to produce functional 15-PGDH, 4T1 cells
were infected with OSVP virus at an MOI of 5, and 48-h.p.i.
supernatants of the infected cells were collected and assayed
for cumulative levels of PGE2. 4T1 cells infected with OSVP or
transfected with the 15-PGDH expression vector alone displayed significantly reduced levels of supernatant PGE2 relative to the no-treatment control (⬎10-fold). In contrast, infection with OS or OSV resulted in remarkable increases in
supernatant PGE2 (Fig. 3).
OSV and OSVP inhibit 4T1 tumor growth. Previously, we
showed that treatment of 4T1 tumors in immunocompetent
BALB/c mice with the OS virus resulted in substantial reduction in tumor growth and metastasis to the lungs and other
organs (26). Similar experiments were performed to assess the
relative abilities of the OSV and OSVP virus to inhibit 4T1
tumors. Mice bearing palpable tumors were treated with four
doses of virus (1 ⫻ 107 PFU/dose) injected intratumorally at
3-day intervals (Fig. 4). Mice treated similarly with PBS served
as negative controls. Separate experiments using heat-inactivated OSVP and UV-inactivated OS failed to reduce tumor
growth compared with PBS controls (data not shown; 26).
Tumor measurements were collected until the mice were
sacrificed at day 20 (posttreatment). All three viruses, OS,
OSV, and OSVP, resulted in similar reductions of tumor
growth (Fig. 4).
OSV and OSVP treatments reduce the incidence of pulmonary metastases. Previously, we showed that OS treatment of
4T1 tumors in BALB/c mice reduced the incidence of tumor
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FIG. 3. PGE2 degradation by OSVP. Nearly confluent monolayers
of 4T1 cells were infected with the indicated viruses at an MOI of 5.
After 2 days culture supernatants were harvested and assayed for
PGE2 by ELISA. P denotes transient expression with a 15-PGDH
mammalian expression vector, while “No Tx” denotes mock-treated
cells. PGE2 assays were performed in triplicates, and error bars represent the 95% confidence interval (CI) of the mean.

FIG. 4. Intratumor treatment with OS, OSV, or OSVP viruses. A
total of 1 ⫻ 105 viable 4T1 cells were implanted subcutaneously in the
interscapular area of BALB/c mice. Tumors were measured using a
digital caliper at defined time intervals prior to and after treatment (x
axis). Median tumor volumes over time are shown on the y axis.
Tumors were injected with each virus (1 ⫻ 107 PFU/ml in PBS buffer),
or PBS alone when tumors reached approximately 80 to 90 mm3 in
volume. Tumor volumes were measured prior to (negative values on
the x axis) and after the injections. Tumors were treated with each virus
at days 1, 3, and 6, as indicated by arrows. The asterisk indicates
statistical significance by nonparametric analysis (31). The results
shown are from one of three independent experiments that produced
similar results.

metastases (25). To determine the abilities of OSV and OSVP
viruses to inhibit development of tumor metastasis, pulmonary
metastatic loads in treated and untreated animals were assessed 30 days post-tumor inoculation, by determining the
number of 6-thioguanine-resistant clonogenic 4T1 cells recoverable from total lung homogenates per mouse (see Materials
and Methods). OSVP treatment significantly reduced the number of recovered pulmonary clonogenic 4T1 cells in comparison to the PBS-treated control. Furthermore, OSVP also reduced the overall incidence of pulmonary metastasis as
determined by the ability to recover clonogenic 6-thioguanineresistant cells (Fig. 5). OS and OSV treatments resulted in
intermediate but not statistically significant reductions in metastatic pulmonary tumors in comparison to PBS, but only OSV
was able to reduce the incidence of pulmonary metastasis,
similar to OSVP. A pairwise comparison of OSV and OSVP
treatments was unable to establish statistically significant differences in metastasis or incidence.
OSVP alleviates PGE2-based immune suppression in mice
with advanced 4T1 tumors. PGE2 promotes the development
and activity of immunosuppressive cell populations, including
MDSC and Treg (53, 57, 58). To examine the effect of 15PGDH expression and the expected PGE2 reduction of immune suppression in mice treated with the OSVP virus, the
relative proportions of splenocytes and lymphocytes of lymph
node origin possessing suppressor cell phenotypes were determined by polychromatic flow cytometry. OSVP-treated mice
exhibited a significant decrease in splenic MDSC compared to
OSV (Fig. 6A). In contrast, splenic Treg were not significantly
reduced (data not shown), although oncolytic therapy alone
appeared sufficient to inhibit some Treg accumulation in lym-
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FIG. 5. Quantification of pulmonary metastases. Virus-treated
mice bearing 4T1 tumors were sacrificed 30 days post-tumor inoculation, and both lungs were harvested from each treated mouse and
homogenized for cell culture. Clonogenic metastatic foci derived from
total lung homogenates were enumerated by limited dilution culture in
the presence of 6-thioguanine. Individual resistant colonies were
counted and used to determine the number of CFU per animal (x axis).
Shown are the calculated CFU of each mouse sorted by treatment.
Means for each treatment group are represented by horizontal bars
with error bars delineating 95% CI. The mean number of metastatic
colonies recovered from the OSVP-treated group was significantly less
than that of the PBS control group (Mann-Whitney test; P ⫽ 0.0474),
but other pairwise comparisons did not prove statistically significant.
The results shown are from one of three independent experiments that
produced similar results. Not all samples yielded colonies, and the
ability to recover colonies was used to determine pulmonary metastasis
incidence rates for each group (shown below the chart).

phocytes from lymph nodes (Fig. 6B). Elevated PGE2 has been
shown to inhibit dendritic cell maturation (20). The proportions of CD83-positive cells (representing mature DC and activated T cells) present in spleens from OSVP-treated mice
were significantly increased relative to PBS-, OS-, or OSVtreated controls (Fig. 6C). Similarly, CD83⫹ lymphocytes were
significantly increased in OSVP-treated animals in comparison
to PBS-, OS-, and OSV-treated controls (Fig. 6D).
Th1/Th2 cytokine profiling was performed to assess the
baseline and stimulated immune activities of splenocytes from
treated and control mice bearing similar-size tumors. Generally, OS, OSV, and OSVP viruses appeared to stimulate unbiased effector helper T cell activity, as evidenced by the production of similar levels of Th1 (interleukin 2 [IL-2],
granulocyte-macrophage colony-stimulating factor [GM-CSF],
and gamma interferon [IFN-␥]) and Th2 (IL-5, IL-4, IL-10,
and IL-12) cytokines in comparison to those of the PBStreated control animals (Fig. 7A). Polyclonal stimulation of
isolated splenocytes with immobilized CD3 antibody produced
a pattern of immune stimulation similar to that of unstimulated splenocytes, with the exception that a significantly more
robust production of the relevant cytokines was observed in
comparison to that of PBS-treated animals (Fig. 7B).
DISCUSSION
We have previously reported that the oncolytic HSV-1(F)based virus OS inhibited primary tumor growth and the formation of metastatic tumors in the 4T1/BALB/c immunocompetent mouse system (25, 26). We sought to arm OS with the
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FIG. 6. Immunophenotypes of draining lymph node lymphocytes and splenocytes. 4T1 tumor-bearing mice with similarly sized and welldeveloped tumors were given a single intratumoral injection of the indicated viruses. After 2 days, cells from draining lymph nodes (B and D) or
spleens (A and C) were isolated and analyzed for MDSC markers (Gr1⫹, CD11b⫹) (A), CD4⫹CD25⫹FoxP3⫹ regulatory T cells (B), and CD83
(C and D). Indicated phenotypes are shown as the mean percentage of total live cells interrogated by flow cytometry (error bars represent 95%
CI of the means) (n ⫽ 3 unless otherwise noted). Asterisks with brackets indicate pairwise statistical significance. Asterisks alone indicate statistical
significance over all pairwise comparisons among the treatments (two-tailed t test; P ⬍ 0.05).

ability to enhance potential antitumor immune responses initiated by treatment of ectopic tumors with OS. To this end, the
OS virus was modified to increase antigen presentation and
viral safety by deleting the vhs (UL41) gene. In addition, OS
was modified to constitutively express 15-PGDH, causing a
reduction of PGE2 accumulation and a concomitant reduction
in the number of MDSC. The resultant OSVP virus showed
enhanced abilities to reduce tumor growth and metastasis in
the 4T1/BALB/c breast cancer mouse model system.
Characteristics of OSV and OSVP oncolytic viruses. Deletion of the vhs gene did not drastically affect virus replication
in Vero or mouse 4T1 cells or virus-induced cell fusion caused
by the gBsyn3 syncytial mutation of the parental OS virus. This
result is in agreement with previous findings that deletion of
the UL41 gene had modest effects on HSV-1 replication in cell
culture (51, 52). The vhs-deleted OSV genome contains an
approximately 11-kbp deletion encompassing the unique long
(UL)-unique short (US) junction (25, 26) and the UL41 (vhs)
deletion (2.5 kbp), for a total of approximately 13.5-kbp deleted sequences. Therefore, this virus is amenable to insertion
of multiple gene cassettes expressing genes of interest to cancer therapy, without exceeding viral DNA packaging limits.
The 15-PGDH gene cassette was inserted in place of the vhs
deletion on the OSV viral genome cloned as a bacterial artificial chromosome (BAC). The OSVP-BAC (bOSVP) was stable in E. coli and did not contain any unintended genetic
alterations, as evidenced by restriction endonuclease analysis
and DNA sequencing (not shown). The OSVP virus appeared

to replicate less efficiently (5-fold less) than either the OS and
OSV viruses, although the syncytial phenotype of the virus was
unaffected. Early work has shown that activation of latent HSV
is usually associated with a local or systemic rise in prostaglandins, including PGE2. Furthermore, exogenously added PGE2
enhanced viral replication, while indomethacin, a nonsteroidal
anti-inflammatory drug that inhibits PGE2, inhibited viral replication (19, 30). The mechanism by which PGE2 facilitates
viral replication and egress is not known. Attempts to rescue
the observed reduction in the viral replication defect of OSVP
virus by adding PGE2 to infected cell cultures failed to increase viral titers (not shown). It is possible that high levels of
intracellular 15-PGDH expression causes substantial reduction
in intracellular PGE2 levels even in the presence of exogenously added PGE2. Typically, PGE2 levels are highly elevated
within tumors, potentially promoting viral replication (17). Expression of 15-PGDH by OSVP is expected to decrease intratumoral PGE2 levels, potentially resulting in lower viral
growth. However, 15-PGDH expression did not drastically reduce viral replication in cell culture (Fig. 2) or within tumors
(not shown), suggesting that basal levels of PGE2 remaining in
tumors after PGDH expression are sufficient for viral replication.
A critical consideration in the use of oncolytic herpesviruses
in human cancer therapy is the provision for multiple safety
measures against uncontrolled propagation of the virus in the
host. The parental OS virus carries a large deletion encompassing the UL-US junction and containing one copy of the
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FIG. 7. Cytokine immunoprofiles of lymphocytes derived from treated mice. Mice with similarly sized 4T1 tumors (200 to 300 mm2) were
treated twice with a 3-day interval. Two days following treatments with OS, OSV, OSVP, or PBS (control), lymphocytes from draining lymph nodes
were isolated and cultured for 24 h alone (A) or with immobilized anti-CD3 stimulatory antibody (B) at a concentration of 100,000 cells per ml.
TNF-␣, tumor necrosis factor alpha. Supernatants were assayed for TH1/TH2 cytokine production by Bioplex (Bio-Rad). Shown are the mean
quantities of the indicated cytokines in pg/ml with error bars representing 95% CI (n ⫽ 3). Shown are results from one of two experiments with
similar results.

ICP34.5 gene, as well as the immediate-early ICP0 and ICP4
genes and one of the two LAT gene loci in the viral genome
(25, 26). This deletion is similar to the deletion carried by the
NV1020 virus that has been tested extensively in preclinical
animal models and recently in human studies, showing a high
safety profile (4, 8, 15, 18, 25, 26, 28, 29). The vhs gene is
known to be critically important for viral pathogenesis. Specifically, deletion of the vhs gene substantially reduced the ability
of the virus to grow in trigeminal ganglia, brains, and corneas.
Furthermore, vhs-deleted viruses failed to cause clinical disease and to establish and reactivate from latency (62–64).
Therefore, deletion of the vhs gene provides for a significant
increase in viral attenuation and safety. The production of
15-PGDH may also provide for an additional level of safety,
since high levels of PGE2 increase viral replication, virus
spread, and reactivation from latency (19, 30).
OS, OSV, and OSVP viruses stimulate broad immune responses. Th1/Th2 cytokine profiling revealed that all three
viruses stimulated the production of similar levels of both Th1
(IL-2, GM-CSF, and IFN-␥) and Th2 (IL-5, IL-4, IL-10, and

IL-12) cytokines. These results suggest that although the absence of the vhs protein and constitutive expression of 15PGDH may directly or indirectly affect dendritic cell functions
and maturation, these effects did not appreciably alter the
potent local and systemic immunostimulatory properties of
these viruses. Moreover the cellular responses to polyclonal T
cell activation were considerably enhanced in treated animals.
The presence of increased CD83-positive cells in draining
lymph nodes of OSVP-treated tumors suggests that OSVP may
provide additional immune enhancement. This robust immune
stimulation may provide, or allow, the necessary inflammatory
signals, which are known to be critical for the generation of
antitumor immune responses (39–41). Importantly, the lack of
the vhs gene may allow increased expression of tumor-associated antigens (TAA) into the tumor microenvironment for
uptake by dendritic cells, leading to adaptive T cell priming.
On the other hand, 15-PGDH expression may help ensure the
overall viability of dendritic cells for optimum TAA presentation by dendritic and other professional antigen-presenting
cells.
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OSVP, but not OS or OSV, viruses reduce levels of MDSC
and increase CD83. CD11b and GR-1 double-positive cells
(MDSC) and Treg, indicated by CD3, FoxP3, and CD25 staining, represent a diverse population of PGE2-sensitive immune
cells with suppressor functions that are induced by many cancers, including 4T1 (reviewed in reference 47). The OSVP
virus substantially reduced the relative numbers of MDSC in
treated animals in comparison to either OS or OSV viruses,
suggesting that the observed MDSC inhibition was caused by
the 15-PGDH expression and the concomitant reduction in
PGE2 levels. The observed MDSC reduction in peripheral
lymphocyte and splenocyte populations suggests that intratumoral expression of 15-PGDH is capable of producing systemic reduction of MDSC. At the same time we observed a
significant increase in CD83⫹ immune cells in response to
15-PGDH, suggesting that OSVP reduces immune suppression
and increases immune activation in part through 15-PGDH
expression. Similar results have been obtained after adenovirus-mediated delivery of 15-PGDH in CT-26 colon carcinomas
implanted in mice. This work showed not only a reduction of
MDSC, but also the differentiation of intratumoral CD11b
cells from immunosuppressive phenotypes to MHC class IIpositive myeloid APCs (10).
OSVP treatment of highly metastatic 4T1 mouse breast tumors resulted in a substantial reduction of metastasis to mouse
lungs. Additional work, however, is needed to determine the
relative contributions of the vhs deletion and 15-PGDH insertion to this reduction. Nevertheless, others have also reported
on the therapeutic effects of 15-PGDH expression in similar
experiments using an adenovirus expressing murine 15-PGDH
to treat murine colorectal tumors. In this system, treated mice
developed antitumor immune responses that caused eradication and long-term survival in 70% of the mice (10). Unlike the
adenovirus vector, the OSVP oncolytic vector platform holds
particular promise for cancer therapy because it can accommodate the simultaneous expression of additional genes that
can stimulate antitumor immune responses and alter the immunosuppressive milieu in the tumor microenvironment. In
addition, the virus can accommodate the heterologous expression of specific TAA that can potentially augment antigenspecific antitumor immune responses. Recently, the NV1020
oncolytic virus, which represents a genomic arrangement similar to that of the OSVP virus, with the exception of the vhs
deletion and constitutive expression of 15-PGDH, was shown
to be safe and efficacious in an expanded phase I/II trial for the
treatment of colorectal metastasis to the liver (15). Similarly,
the true potential of the OSVP virus for cancer treatment has
to be demonstrated in human clinical trials.
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